By 2030, will the FDA approve any drug in combination with a checkpoint blockade therapy that substantially reduces immune escape?
GeopolitiekOne-OffGezondheid en geneeskunde3j
Manifold MarketsGeen KYCGeverifieerde afwikkelingsgegevensRedelijk gekalibreerdHuidige gemeenschapsvoorspellingJa 53.5%
Voorspellers
5
Vraagtype
binary
Methodologie
Play-money forecasting platform
Brontype
Voorspelling
Marktdata
Bijgewerkt 24 minuten geleden
18 nov 22, 02:41 UTC1 jan 30, 08:00 UTC
Trends
Regels
Checkpoint blockade therapy (also called immune checkpoint inhibitors) is an cancer therapy that works (roughly speaking) by preventing the cancer from disabling the immune system.
- There's a list of major immune checkpoint inhibitors here: https://en.wikipedia.org/wiki/Checkpoint_inhibitor
- A common issue with this kind of therapy is immune escape: the cancer mutates and escapes from the immune system in some other way, which makes the drug much less effective or even useless.
- You can read an overview of the topic here: https://sci-hub.se/10.1093/annonc/mdw217
- This market resolves YES if any combination therapy is approved that:
- Reduces immune escape by >= 10 percentage points over the course of two years according to any metric in an associated publication.
